|
| Day 0, administration of SARS-CoV-2 Pfizer-BioNTech mRNA vaccine | Day +2, visits family physician | Day +10, visits family physician | Day +33 | Day +59 | Day +62, presentation to the SUMC | Day +63, diagnosis made of SLE |
|
Clinical manifestations | | Appearance of facial rash; nonspecific joint pain | Facial rash, morning stiffness, arthralgia, and fatigue | Progression of rash on the face, neck, and arms, nonscarring hair loss over the head, joint pain, and stiffness | Psoriasiform-papulosquamous plaques over the face, neck, and arms, nonscarring hair loss over the head, stress pain at the wrists without a sign of effusion, and joint pain with morning stiffness lasting up to two hours |
Treatment | | Calamine topical | Calamine topical and fexofenadine trima tablet 180 mg | Hydroxychloroquine 200 mg BID; mometasone furoate cream 0.1% for topical use QD; and etoricoxib 90 mg QD as needed |
Laboratory testing | | Positive COVID-19-neutralizing antibodies | ANA:1:160, with a speckled pattern and positive anti-chromatin (nucleosomal) and ribosome P antibodies (1.6AI, >8.0AI, respectively). C3 and C4 levels: 70 mg/dL and 21 mg/dL, respectively | |
|